What is the primary purpose of this acquisition for Gilead Sciences?

While the filing doesn't explicitly detail YM Biosciences' assets, acquisitions of this nature typically aim to enhance Gilead's drug pipeline, expand its therapeutic reach, or acquire promising late-stage development candidates or commercialized products. Investors should look for further company communications regarding the strategic rationale.

What are the key conditions that must be met before the acquisition closes?

Key conditions include approval by YM Biosciences' shareholders, approval from the Supreme Court of Nova Scotia, expiration or termination of the waiting periods under the Hart-Scott-Rodino Act in the U.S. and the Competition Act in Canada, absence of legal restraints, accuracy of YM's representations and warranties, YM's compliance with covenants, and no material adverse change in YM's business.

Does Gilead's acquisition of YM Biosciences require a vote from Gilead shareholders?

No, the filing explicitly states that the transaction does not require the approval of Gilead's stockholders.

What is the expected timeline for the completion of this acquisition?

Gilead currently expects the transaction to close in the first quarter of 2013.

GILD 8-K: Material Agreements

Summary

Gilead Sciences, Inc. (GILD) has entered into a definitive agreement to acquire YM Biosciences Inc. for approximately $510 million in cash. YM Biosciences is a Nova Scotia-based company, and upon completion of the arrangement, it will become a wholly-owned subsidiary of Gilead. This strategic move is expected to close in the first quarter of 2013, subject to customary closing conditions including shareholder and court approvals, as well as regulatory clearances. This acquisition represents Gilead's commitment to expanding its pipeline and therapeutic offerings. Investors should monitor the closing process and any further announcements regarding the integration of YM Biosciences' assets and operations. The deal's approval process involves antitrust reviews in both the U.S. (Hart-Scott-Rodino) and Canada.

Key Highlights

1Gilead Sciences to acquire YM Biosciences Inc. for approximately $510 million in cash.
2The acquisition is structured as a plan of arrangement, with YM Biosciences becoming a wholly-owned subsidiary of Gilead.
3The transaction is expected to close in the first quarter of 2013.
4Closing is contingent upon YM shareholder approval, Supreme Court of Nova Scotia approval, and antitrust clearances in the U.S. and Canada.
5The agreement includes standard representations, warranties, and covenants.
6The transaction does not require approval from Gilead's stockholders.

GILEAD SCIENCES, INC. 8-K Report, Material Agreement (Dec 12, 2012)

Summary

Key Highlights

Frequently Asked Questions